3M Health Care has announced the launch of a new medical diagnostics business unit. This division will be focused on the development and commercialisation of products aimed at the detection of microbes that are resistant to treatment, such as methicillin-resistant Staphylococcus aureus (MRSA) and other infectious pathogens.
These products will be made available to hospitals to facilitate the speedy detection of such microbes before their potential spread and infection of patients, with the intention of improved patient outcomes with lower costs and enhanced profitability.
With an expected release date of 2007, rapid diagnostic tests from the firm will simplify the procedure of testing for these pathogens and provide results for the detection of MRSA, influenza and other diseases faster than existing methods.
Angela Dillow, global business manager at the company, said: "3M Medical Diagnostics is a natural extension of our infection prevention platform and enables us to offer hospitals a full spectrum of products that detect, prevent and treat infections in the hospital setting."
She added that the company had observed trends in the healthcare market suggesting the demand for easy-to-use and fast microbial diagnostics products for the control and prevention of such infection worldwide.
Last month, 3M announced that it had acquired UK-based automated microbial detection firm Acolyte Biomedica.See all the latest jobs in Medical Devices